10, 2015 /PRNewswire/ -- Palatin
AMEX: CTT) announced today that it has filed for arbitration against Palatin
The research work was conducted as part of sponsored research agreement between Temple University School of Medicine and Palatin
AMEX: CTT) today announced that it has filed a complaint against licensee Palatin
initiated Protocols 301 and 302 of its Phase 3 reconnect study in the United States and Canada for the treatment of FSD in December 2014 and January 2015, respectively.
AMEX: CTT) today announced that it was taking exception to certain statements included in the recently filed Form 10-K of its licensee Palatin
President and Chief Executive Officer of Palatin
Technologies stated, "We are excited by the potential of PT-141 as a treatment for FSD.
believes that these clinical trial results demonstrate that NeutroSpec potentially represents a significant advancement in the diagnosis of occult infections and pedal osteomyelitis.
March 6, 2015 /PRNewswire/ -- Palatin
president and chief executive officer, Palatin
president and chief executive officer of Palatin
, will present a corporate overview and update on the status and progress of the Company, including its lead products under development: PT-141, the Company's lead drug candidate currently in Phase II studies for male and female sexual dysfunction, and NeutroSpec(TM), its proprietary radiolabeled monoclonal antibody for imaging and diagnosing infections.
13, 2014 /PRNewswire/ -- Palatin